Charles River Laboratories International (NYSE:CRL) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Charles River Laboratories International (NYSE:CRL) from a buy rating to a hold rating in a report released on Saturday.

Other equities research analysts have also issued research reports about the company. Robert W. Baird raised Charles River Laboratories International from a “neutral” rating to an “outperform” rating and increased their price target for the company from $178.00 to $199.00 in a research report on Thursday, November 6th. Jefferies Financial Group raised shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and raised their price objective for the stock from $142.00 to $195.00 in a report on Tuesday, September 9th. Argus set a $200.00 target price on shares of Charles River Laboratories International in a report on Monday, November 17th. Barclays lifted their price target on shares of Charles River Laboratories International from $195.00 to $210.00 and gave the stock an “overweight” rating in a research note on Thursday, November 6th. Finally, JPMorgan Chase & Co. boosted their target price on Charles River Laboratories International from $160.00 to $165.00 and gave the company a “neutral” rating in a report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average target price of $194.07.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $197.97 on Friday. Charles River Laboratories International has a 1-year low of $91.86 and a 1-year high of $200.58. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.37 and a quick ratio of 1.10. The firm has a market capitalization of $9.74 billion, a price-to-earnings ratio of -126.90, a PEG ratio of 6.82 and a beta of 1.63. The company’s 50-day moving average is $177.86 and its two-hundred day moving average is $164.09.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, beating analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 2.07% and a positive return on equity of 15.78%. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $990.43 million. During the same period last year, the business earned $2.59 earnings per share. The business’s revenue for the quarter was down .5% on a year-over-year basis. Analysts forecast that Charles River Laboratories International will post 9.36 EPS for the current year.

Institutional Investors Weigh In On Charles River Laboratories International

Hedge funds and other institutional investors have recently made changes to their positions in the business. Brooklyn Investment Group lifted its position in shares of Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 86 shares during the period. Cromwell Holdings LLC raised its stake in Charles River Laboratories International by 542.9% in the second quarter. Cromwell Holdings LLC now owns 180 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 152 shares in the last quarter. Neo Ivy Capital Management bought a new stake in Charles River Laboratories International during the second quarter worth about $29,000. Rothschild Investment LLC increased its holdings in Charles River Laboratories International by 82.4% in the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after buying an additional 84 shares during the period. Finally, Atlantic Union Bankshares Corp acquired a new position in shares of Charles River Laboratories International in the 3rd quarter valued at approximately $31,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).